AMPK is also important in BCR-ABL-induced chronic myeloid leukemia (CML) and AMPK pathway activators may prove useful as combination drug therapy (with BCR-ABL inhibitors) for this disease [171]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.